Payers

As oncology practices transition to value-based care, they are challenged to take on more holistic responsibility for their patient. Fortunately, the examples of practices participating in CMS’ Oncology Care Model can offer valuable insight into the most impactful workflow changes providers can implement as they strive to achieve cost and quality improvements.

A chief medical officer for a major payer outlines the challenges making sure that certain high-cost therapies are directed to the patients who need them.

The rate of healthcare spending in the United States slowed down last year to levels previously seen between 2008-2015, driven by much slower growth in spending for retail prescription drugs, as well as hospital care and physician and clinical services. Private payers, Medicaid, and Medicare­ also saw lower rates of spending growth.

Mind-body practices have increased in popularity,but the challenge of variation between teachers and classes has been a barrier to payer reimbursement.

The authors, both members of the Digestive Health Physicians Association, write about efforts in their home state and at the federal level to reform payer restrictions.

The rule has several proposals that may be attractive to insurers in the area of risk adjustment.

Representatives from 3 payers who partnered with providers on the Oncology Care Model (OCM) took the stage at Community Oncology Alliance (COA)’s Payer Exchange Summit on Oncology Payment Reform to outline their experience with OCM and how it has differed from other care models.

The implementation of the Oncology Care Model has brought profound culture changes to how oncologists take care of patients and how they operate practices, explained Lucio Gordan, MD, of Florida Cancer Specialists.

Scaling behavioral change and reducing diabetes at the population level were major themes of the meeting.

The CEO said the changes will finally allow the company to set the inhaled insulin apart from its rivals.

The move to give entrepreneurs access to patient-approved continuous glucose monitoring data fits with the company's prediction that insulin pumps will become a thing of the past, and most of the heavy lifting of delivery will be done by a smartphone.

The growing importance of quality ratings will put pressure on hospitals to meet ADA standards for insulin therapy without added manpower.

Studies presented at the American Diabetes Association Scientific Sessions showed that patients being treated with the ITCA 650 were less likely to need to take additional therapy to control their diabetes.

Patients, payers, and providers all view value in different ways, and they all need to be taken into account in value frameworks, said Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow.

Coverage from the 2017 meeting of the American Association of Diabetes Educators.

Jennifer Graff, PharmD, vice president of comparative effectiveness research at the National Pharmaceutical Council, discusses where payers receive their information and how it is used to make decisions about coverage and reimbursement.

By aligning payers to care about population health and social determinants of health, it will help improve the health of the community as a whole, said Michael Griffin, president and CEO of Daughters of Charity Services.

Payers acknowledge obesity as a public health issue and are working to establish offerings that align with USPSTF recommendations in order to treat and prevent obesity, says Jenny Bogard, MPH, director of healthcare strategies at the Alliance for a Healthier Generation.

All stakeholders stand to gain from the 340B program in different ways, but they also take on different risks, like the potential impact for health plans on rebate contracts, said Neil Minkoff, MD, chief medical officer of EmpiraMed.

The #Coverage2Control campaign begins a year after the announcement that UnitedHealth would shift most adult type 1 diabetes patients toward Medtronic technology, or require them to pay significant out-of-pocket costs. More significantly, JDRF reports payers are saying they will not fund the artificial pancreas.

The 340B program has evolved significantly since its passage, but there are still important changes needed, like clarifying the target patient population. The complicated rebate system for payers and drug manufacturers is also a consequence that should be addressed, said Neil Minkoff, MD, chief medical officer of EmpiraMed.

While it remains to be seen how the Trump administration deals with healthcare fraud, preventing fraudulent practices within your organization should be a priority-unless you want to be held personally liable.

The National Pharmaceutical Council (NPC) today published a letter outlining its thoughts on the FDA draft guidance regarding manufacturer communications about off-label uses of drugs. Today was the final day to comment on the draft before the agency begins to formulate the final version of the guidance.

At the American College of Cardiology Scientific Session, a study of prescriptions for PCSK9 inhibitors confirms what doctors say about trying to get their patients access to the cholesterol drug.